The importance of ePRO to support NASH/NAFLD unmet clinical research and medical needs
NonAlcoholic SteatoHepatitis (NASH), now called Metabolic Dysfunction-Associated SteatoHepatitis (MASH), affects almost 115 million adults globally
2022 Employee satisfaction survey
98% of our employees are satisfied or very satisfied with their relationship with their colleagues and their management: discover the full results of our 2022 employee survey below and browse our job offers here!
Learn more:
NonAlcoholic SteatoHepatitis (NASH), now called Metabolic Dysfunction-Associated SteatoHepatitis (MASH), affects almost 115 million adults globally
In this second episode on pediatric clinical trial challenges, Begoña Nafria, pediatrician and patient engagement
Ophthalmic conditions and vision impairment currently affect 2.2 billion people globally. Data collection can be
In contrast to paper solutions, electronic Clinical Outcome Assessment (eCOA) demonstrates strengths such as: Accuracy
Early phase clinical research (phase 1 and 2a) focuses on characterizing the behavior of the
In a clinical trials environment that is moving increasingly towards digitalization and decentralization, it remains
Last update : 2 March 2023